Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 06996 ANTENGENE-B > Company Profile
06996 ANTENGENE-B
4.100
+0.110+2.76%
Symbol
06996
Company Name
ANTENGENE-B
ISIN
KYG039571008
Listing Date
11/20/2020
Establishment Date
08/28/2018
Registration
Cayman Islands
Chairman
Jianming Mei
Secretary
Yang;wangchengzhang Cao
Audit Institution
Ernst & Young accounting firm
Company Category
Other
Registered Office
Maples Corporate Services Limited's office PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business
Room 901, 9 / F, Nan Fung Building, 88 Connaught Road Central and 173 des Voeux Road Central, Hong Kong
Fiscal Year Ends
12-31
Employees
383
Market
Hong Kong motherboard
Phone
(0221)88888888
Fax
(0221)88888888
Email
ir@antengene.com
Business
Deqi Pharmaceutical Co., Ltd. is a clinical stage biopharmaceutical company in the Asia-Pacific region focusing on the innovation of antineoplastic drugs. The company is mainly engaged in the discovery, development, production and commercialization of biotechnology products. The company's key products include ATG-010 (selinexor) for the treatment of recurrent / refractory multiple myeloma, recurrent / refractory diffuse large B-cell B-cell lymphoma and non-small cell lung cancer, and ATG-008 (onatasertib) for a variety of indications, including hepatocellular carcinoma and non-small cell lung cancer. The company mainly operates in the Asia-Pacific region.
Profile
Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative antineoplastic drugs. Our uniqueness comes from our industry-leading R & D capabilities and differentiated strategic approaches to developing new antineoplastic therapies. Our vision is to discover, develop and commercialize the world's first, unique and / or best-of-class therapy, treat patients without borders and improve their living standards. Through the effective use of resources, outstanding ability in target selection and differentiated R & D strategy, Deqi Pharmaceuticals has established a strong and highly coordinated R & D pipeline of 12 products, including two late clinical assets and four early clinical assets. In addition, we are developing six pre-clinical R & D drugs that focus on innovative targets or mechanisms and have the potential to be number one in their class to address huge unmet medical needs. Moreover, these drugs target the key pathways of carcinogenesis and have the potential to be combined with each other. Since its inception, we have established a solid R & D framework in the Asia-Pacific region and have a pan-Asia-Pacific clinical R & D capability. At this stage, we are establishing a commercialization team in the Asia-Pacific region to support the recent product launch, which is made up of multinational leaders with rich business experience and experienced practitioners who have in-depth knowledge of the developments in each local market.
Company Overview
Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative antineoplastic drugs. Our uniqueness comes from our industry-leading R & D capabilities and differentiated strategic approaches to developing new antineoplastic therapies. Our vision is to discover, develop and commercialize the world's first, unique and / or best-of-class therapy, treat patients without borders and improve their living standards. Through the effective use of resources, outstanding ability in target selection and differentiated R & D strategy, Deqi Pharmaceuticals has established a strong and highly coordinated R & D pipeline of 12 products, including two late clinical assets and four early clinical assets. In addition, we are developing six pre-clinical R & D drugs that focus on innovative targets or mechanisms and have the potential to be number one in their class to address huge unmet medical needs. Moreover, these drugs target the key pathways of carcinogenesis and have the potential to be combined with each other. Since its inception, we have established a solid R & D framework in the Asia-Pacific region and have a pan-Asia-Pacific clinical R & D capability. At this stage, we are establishing a commercialization team in the Asia-Pacific region to support the recent product launch, which is made up of multinational leaders with rich business experience and experienced practitioners who have in-depth knowledge of the developments in each local market.
CEO: Jianming Mei
Market: Hong Kong motherboard
Listing Date: 11/20/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist